- |||||||||| Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Clinical, Clinical data, Retrospective data, Review, Journal, Adverse events: Clinical Outcomes and Adverse Events after First-Line Treatment in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis. (Pubmed Central) - Jan 21, 2022 N+C may provide the most favorable OS, L+P the most favorable PFS and ORRs, while N+I the lowest toxicity. Population differences may potentially undermine the generalizability and the robustness of findings.
- |||||||||| lenvatinib / Generic mfg.
Journal: Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer. (Pubmed Central) - Jan 19, 2022 In this real-life clinical experience, lenvatinib showed interesting results as salvage therapy in patients with advanced progressive metastatic MTC patients. Its usefulness could be effective in patients without any other available treatment, because previously used or unsuitable, especially with negative RET status with no access to the new highly selective targeted therapies.
- |||||||||| Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Retrospective data, Journal, Adverse events: Cardiovascular Toxicities of Antiangiogenic Tyrosine Kinase Inhibitors: A Retrospective, Pharmacovigilance Study. (Pubmed Central) - Jan 19, 2022 Hypertension, aortic dissections, and pericardial diseases had the highest reporting odds ratios. While the association of VEGFR-TKIs with hypertension is well established, pericardial diseases were not observed to date, and aortic dissection was reported in a small case series.
- |||||||||| Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS, Nexavar (sorafenib) / Bayer, Amgen
Clinical, Review, Journal, Checkpoint inhibition: Comparative safety and efficacy of molecular-targeted drugs, immune checkpoint inhibitors, hepatic arterial infusion chemotherapy and their combinations in advanced hepatocellular carcinoma: findings from advances in landmark trials. (Pubmed Central) - Jan 14, 2022 Here, we present preliminary evidence for the comparative safety and efficacy of existing MTDs, ICIs, HAIC and their combinations in AHCC, which indicated that HAIC-oxaliplatin monotherapy has acceptable toxicity and efficacy and could be the cornerstone for future combination of systemic treatments in AHCC. Our findings might provide insight into the future design of multidisciplinary treatments in AHCC.
- |||||||||| lenvatinib / Generic mfg.
Biomarker, Journal: circRNA circMED27 acts as a prognostic factor and mediator to promote lenvatinib resistance of hepatocellular carcinoma. (Pubmed Central) - Jan 14, 2022 Our mechanistic investigations revealed that circMED27 functions as a competing endogenous RNA (ceRNA) for miR-655-3p to upregulate ubiquitin-specific peptidase 28 (USP28) expression. Thus, we are led to conclude that circMED27 acts as a potential therapeutic target for HCC patients receiving lenvatinib therapy and may represent a promising molecular biomarker for forecasting lenvatinib-resistant HCC.
- |||||||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Combination therapy: A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma (clinicaltrials.gov) - Jan 13, 2022 P2, N=72, Active, not recruiting, In conclusion, DEB-TACE+LEN conferred better ORR, OS and TTP than did DEB-TACE+SOR in patients with advanced HCC, especially those with PVTT and FGF21 amplification, with acceptable AEs; thus making it a superior treatment modality for these patients. Recruiting --> Active, not recruiting
- |||||||||| Avastin (bevacizumab) / Roche, Nexavar (sorafenib) / Bayer, Amgen
Clinical, Retrospective data, Review: First-Line Systemic Treatment Strategies for Unresectable Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials. (Pubmed Central) - Jan 11, 2022 Sintilimab plus bevacizumab, atezolizumab plus bevacizumab, lenvatinib, and linifanib had better PFS outcomes than sorafenib...Thus, sintilimab plus bevacizumab may be a better first line choice for the treatment of patients with unresectable HCC. PROSPEROI [https://www.crd.york.ac.uk/PROSPERO/index.php], identifier CRD42021269734.
- |||||||||| Nexavar (sorafenib) / Bayer, Amgen
Journal: Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells. (Pubmed Central) - Jan 7, 2022 Overall, the findings suggest that the underlying mechanism of lenvatinib in overcoming sorafenib resistance in HCC involves FGFR4-ERK signaling. Lenvatinib may be a suitable second-line therapy for unresectable HCC patients who have developed sorafenib resistance and express FGFR4.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date: Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC) (clinicaltrials.gov) - Jan 6, 2022 P2, N=60, Active, not recruiting, TACE combined with lenvatinib plus sintilimab is a promising therapeutic regimen in unresectable hepatocellular carcinoma. Trial completion date: Sep 2022 --> Sep 2024 | Trial primary completion date: Oct 2021 --> Oct 2022
|